Glenmark Offering New Firazyr Generic in US

Glenmark Offering New Firazyr Generic in US

295212

Glenmark Offering New Firazyr Generic in US

The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection), a medication to treat acute swelling attacks in patients with hereditary angioedema (HAE), Glenmark Pharmaceuticals, announced in a press release. According to the India-based company, the newly approved generic will be available in a pre-filled 30 mg/3 mL single-use syringe. It will be manufactured in Glenmark’s North American manufacturing facility in Monroe, North Carolina. Firazyr was approved by the FDA nearly…

You must be logged in to read/download the full post.